Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
1
Citations
NaN
KQI